Xanomeline-Trospium Chloride (KarXT) for Schizophrenia

Introducing KarXT: A New Paradigm

on May 1, 2024, JAMA Psychiatry published the positive results of EMERGENT-3 trials for this potential non-dopaminergic medication for schizophrenia. 

KarXT is a combination of two drugs: xanomeline and trospium chloride. This innovative therapy represents a significant departure from traditional antipsychotic treatments.

  • Xanomeline, a muscarinic receptor agonist, targets the cholinergic system in the brain, which is believed to play a crucial role in the symptoms of schizophrenia.
  • Trospium chloride, on the other hand, is a muscarinic receptor antagonist that does not cross the blood-brain barrier, mitigating the peripheral side effects of xanomeline without diminishing its central therapeutic effects.

(1) KarXT: Likely Mechanism of Action:

WATCH YOUTUBE VIDEO FOR DETAILS:

(2) KarXT: How to Dose?

FOR ACADEMY MEMBERS:

Xanomeline-Trospium Chloride (KarXT) for Schizophrenia

This video discussion is summarized in the following sections:

  1. Mechanism of Action: how is this different from other antipsychotics?
  2. Dosing: How to Dose & Titrate?
  3. Effectiveness: is this effective for both positive and negative symptoms of schizophrenia?
  4. Response Time: How early is the response seen with KarXT?
  5. Common side effects
  6. What is the risk of EPSWeight Gain and Somnolence?
  7. Results from EMERGENT-3 trial (Phase 3 Double-blind, Randomized, Placebo-controlled trial): published in JAMA Psychiatry on May 1, 2024.

Xanomeline-Trospium Chloride (KarXT) for Schizophrenia

FOR ACADEMY MEMBERS
ACADEMY

INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?

JOIN ACADEMY MEMBERSHIP:

This is a closed membership for medical professionals only.

  • 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
GENERAL
$ 150/YR
  •  
STUDENTS
$ 99/YR
  •  

DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.

Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com

© 2024 All Rights Reserved.

Related Articles